DE69534701D1 - Verfahren zur behandlung von entzündlichen gelenkerkrankungen - Google Patents

Verfahren zur behandlung von entzündlichen gelenkerkrankungen

Info

Publication number
DE69534701D1
DE69534701D1 DE69534701T DE69534701T DE69534701D1 DE 69534701 D1 DE69534701 D1 DE 69534701D1 DE 69534701 T DE69534701 T DE 69534701T DE 69534701 T DE69534701 T DE 69534701T DE 69534701 D1 DE69534701 D1 DE 69534701D1
Authority
DE
Germany
Prior art keywords
treatment
joint diseases
inflammatory joint
inflammatory
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534701T
Other languages
English (en)
Other versions
DE69534701T2 (de
Inventor
Yi Wang
Louis Matis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69534701D1 publication Critical patent/DE69534701D1/de
Publication of DE69534701T2 publication Critical patent/DE69534701T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69534701T 1994-09-23 1995-09-21 Verfahren zur behandlung von entzündlichen gelenkerkrankungen Expired - Lifetime DE69534701T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31148994A 1994-09-23 1994-09-23
US311489 1994-09-23
PCT/US1995/012404 WO1996009043A1 (en) 1994-09-23 1995-09-21 Methods for the treatment of inflammatory joint disease

Publications (2)

Publication Number Publication Date
DE69534701D1 true DE69534701D1 (de) 2006-01-26
DE69534701T2 DE69534701T2 (de) 2006-10-19

Family

ID=23207113

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534701T Expired - Lifetime DE69534701T2 (de) 1994-09-23 1995-09-21 Verfahren zur behandlung von entzündlichen gelenkerkrankungen

Country Status (8)

Country Link
US (2) US20030175267A1 (de)
EP (1) EP0777474B1 (de)
JP (1) JP3971797B2 (de)
AU (1) AU3729295A (de)
CA (1) CA2198706C (de)
DE (1) DE69534701T2 (de)
ES (1) ES2252746T3 (de)
WO (1) WO1996009043A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608133D0 (en) * 1996-04-19 1996-06-26 Gemini International Holdings Diagnostic method and apparatus
US6998468B2 (en) 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
US20060241074A1 (en) * 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
MXPA04001301A (es) * 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
US6719443B2 (en) 2002-02-27 2004-04-13 Robert A. Gutstein Electrically illuminated flame simulator
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
WO2008030505A2 (en) 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
EP2148691B1 (de) * 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analoga zur behandlung von entzündungserkrankungen der atemwege
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
AU2012340107B2 (en) 2011-11-18 2017-06-15 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
WO2018075761A1 (en) * 2016-10-19 2018-04-26 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
US11965884B2 (en) * 2016-10-19 2024-04-23 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5 in a sample
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785967T2 (de) 1986-04-28 1993-12-02 Cetus Corp Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung.
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
DK0730608T3 (da) * 1993-05-17 2002-07-22 Avant Immunotherapeutics Inc Præparater omfattende komplementrelaterede proteiner og carbohydrater og fremgangsmåder til fremstilling og anvendelse af præparaterne
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
AU2191795A (en) * 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis

Also Published As

Publication number Publication date
JPH10506113A (ja) 1998-06-16
WO1996009043A1 (en) 1996-03-28
EP0777474A1 (de) 1997-06-11
CA2198706A1 (en) 1996-03-28
DE69534701T2 (de) 2006-10-19
AU3729295A (en) 1996-04-09
JP3971797B2 (ja) 2007-09-05
US7279158B2 (en) 2007-10-09
EP0777474A4 (de) 2000-07-26
ES2252746T3 (es) 2006-05-16
US20050226870A1 (en) 2005-10-13
CA2198706C (en) 2008-07-08
US20030175267A1 (en) 2003-09-18
EP0777474B1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69624116D1 (de) Verfahren zur behandlung von allergischem asthma
DE69434672D1 (de) Verfahren zur behandlung von hühnereiern
ATE323500T1 (de) Verfahren und zusammensetzung zur behandlung von verzögerten allergischen reaktionen und entzündungskrankheiten
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
EP0785785A4 (de) Verfahren zur bekämpfung von mit neuropeptiden zusammenhängenden erkrankungen
EP0820467A4 (de) Verfahren zur behandlung von augenkrankheiten
DE69818648D1 (de) Verfahren zur behandlung keimblättriger pflanzen
DE69427774D1 (de) Kontinuierliches verfahren zur behandlung von nahrungsmitteln
DE69707033D1 (de) Verfahren zur Behandlung von Gasen die Organohalogenzusammensetzungen enthalten
DE69814467D1 (de) Verfahren zur prophylaktischen behandlung von mastitis
DE69526796D1 (de) Verfahren zur inhibierung von pflanzenkrankheiten
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69937624D1 (de) Verfahren zur Behandlung von Metalloberflächen
EP0777474A4 (de) Verfahren zur behandlung von entzündlichen gelenkerkrankungen
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
DE69702997D1 (de) Verfahren zur Behandlung von verunreinigtem Aluminiumoxid
DE69331992D1 (de) Verfahren zur hochaufreinigung von menschlichem serumalbumin
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
ATE198751T1 (de) Azoderivate von 5-aminosalicylsäure zur behandlung von enzündlichen darmerkrankungen
DE69328615D1 (de) Verfahren zur behandlung von viehhaltungsgülle
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition